Facebook
Twitter
LinkedIn
ForwardPassport for Care: A Useful Resource for the Delivery of Care to Childhood Cancer Survivors
Needs Statement
Over 80% of childhood cancer patients become survivors of childhood cancer. However, survivors may be at risk for long-term late effects of their treatments with chemotherapy, radiation, surgery, and other modalities. Over time, therapy has been modified to reduce the late effects by using more intensified approaches for those at greatest risk and lessening therapeutic applications where that can be done. However, even survivors treated over the last two decades are at risk may be at risk for serious or life-threatening late effects. While excellent, comprehensive guidelines have been developed by the NIH-supported Children’s Oncology Group, their application can be challenging to implement in the clinic particularly when clinicians may not have access to a survivorship care plan for the survivor listing the history of treatment exposures. The Passport For Care (PFC) is a clinical decision support tool, that is freely available to clinicians and to survivors themselves and makes available a survivorship care plan and guideline-based recommendations tailored to the survivor’s history of treatment exposure. This module introduces the PFC to clinicians, its benefits, and how it may be used to guide follow-up screening for late effects of cancer treatment.
Target Audience
Internists, primary care physicians, nurses, physician assistants, medical trainees and students.
Learning Objectives
At the conclusion of the conference, participants should be able to:
- Discuss the frequency of and source of risks facing long-term survivors of childhood cancer.
- Describe the role for survivorship care plans in screening for late effects of cancer treatments.
- Articulate how a clinical decision support tool can support delivering care in alignment with national guidelines.
Educational Methods
Lecture and Resources
Activity Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.
Method of Participation
This activity includes one didactic lecture delivered in an online enduring material module with contacts provided for implementation of the free tool.
To receive a certificate you should:
- View the presentation in this enduring material.
- Complete and submit the CME/CE evaluation form.
The estimated time to complete this activity, including review of the materials, is 0.25 hour(s).
Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.
If you have questions about the participation process, please contact the Division of Continuing Professional Development by email cpd@bcm.edu or phone 713.798.8237.
Term of Approval
April 1, 2022 through March 31, 2024. Original release date: April 2022
Disclaimer
This CE activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.
Baylor College of Medicine makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site's terms and conditions of use including copyright and licensing restrictions.
Drug/Device Status Disclosure
Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.
Baylor College of Medicine requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.
Disclosure Policy
Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CME activities that are scientifically based, accurate, current, and objectively presented.
In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.
In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME’s validation of clinical content statements.
BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.
All of the relevant financial relationships listed for these individuals have been mitigated.
The following individual(s) has/have reported no financial or other relationships with commercial entities whose products/services may relate to the educational content of this activity:
Michael Fordis, M.D., Activity Director, Planning Committee Member
Director, Center for Collaborative and Interactive Technologies
Senior Associate Dean for Continuing Professional Development
Director of the Institute for Continuing Professional Development in Quality Improvement and Patient Safety
Baylor College of Medicine
Disclosure: Nothing to disclose
Maria Monica Gramatges, M.D., Presenter, Planning Committee Member
Associate Professor, Pediatrics
Associate Chief, Section of Oncology at the Texas Children’s Cancer and Hematology Centers
Co-Director of Long-Term Survivor Program
Baylor College of Medicine
Disclosure: Nothing to disclose
Marc Horowitz, M.D., Planning Committee Member
Professor, Pediatrics—Hematology and Oncology
Baylor College of Medicine
Disclosure: Nothing to disclose
David Poplack M.D., Planning Committee Member
Professor, Pediatrics—Hematology and Oncology
Baylor College of Medicine
Disclosure: Nothing to disclose
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Participation